Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
CTLA-4 (human)

Overview
CTLA-4 Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. 4 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: Membrane protein, integral; Immunoglobulin superfamily
Chromosomal Location of Human Ortholog: 2q33
Cellular Component: Golgi apparatus; perinuclear region of cytoplasm; integral to plasma membrane; plasma membrane; clathrin-coated endocytic vesicle; external side of plasma membrane
Molecular Function: protein binding
Biological Process: B cell receptor signaling pathway; negative regulation of T cell proliferation; positive regulation of apoptosis; negative regulation of regulatory T cell differentiation; T cell costimulation; negative regulation of immune response; immune response; negative regulation of B cell proliferation; response to DNA damage stimulus
Reference #:  P16410 (UniProtKB)
Alt. Names/Synonyms: activation-inducible lymphocyte immunomediatory molecule; AILIM; CD152; CD278; CTLA-4; CTLA4; Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; ICOS; inducible costimulator; inducible T-cell co-stimulator; inducible T-cell costimulator; MGC39850
Gene Symbols: CTLA4
Molecular weight: 24,656 Da
Basal Isoelectric point: 6.7  Predict pI for various phosphorylation states
Select Structure to View Below

CTLA-4

Protein Structure Not Found.


STRING  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  DISEASE  |  Scansite  |  Pfam  |  RCSB PDB  |  Phospho3D  |  Phospho.ELM  |  NetworKIN  |  Source  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Sites Implicated In
intracellular localization: Y201‑p, Y218‑p
molecular association, regulation: Y201‑p, Y218‑p

Modification Sites and Domains  

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 1 S55-p ASSRGIAsFVCEyAS
0 1 Y60-p IAsFVCEyASPGKAT
5 1 Y201-p SPLTTGVyVKMPPTE
3 0 Y218-p CEKQFQPyFIPIN__
  mouse

 
S55 ASSHGVASFPCEYSP
Y60 VASFPCEYSPSHNTD
Y201-p SPLTTGVyVKMPPTE
Y218-p CEKQFQPyFIPIN__
  rat

 
S55 ASSHGVASFPCEYAS
Y60 VASFPCEYASSHNTD
Y201-p SPLTTGVyVKMPPTE
Y218 CEKQFQPYFIPIN__
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.